Expectations for Novartis' canakinumab as an oncology therapy were already fading fast, and have now been nixed after a third phase 3 trial in non-small cell lung cancer (NSCLC) failed to meet its ...
The results of a phase III trial confirm the place of canakinumab in the treatment arsenal for these disorders. Cryopyrin-associated periodic syndromes (CAPS) are a family of related conditions ...
Novartis noted in its statement the other ongoing studies of canakinumab in NSCLC – these include the phase 3 CANOPY-1 trial testing it in combination with Merck & Co’s PD-1 immunotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback